Revolution Medicines, Inc. (RVMDW) stock
RVMDWNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as RVMD
$9.81+0.18 (+1.82%)
Close on Oct 30, 2026Market cap $41.00BP/E –Yield –
Revolution Medicines operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Revolution Medicines's operating cash flow for the twelve months ending Jun 30, 2026 was -$1.22B. For fiscal 2025 it was -$897.74M. The highest annual figure on record is $1.21M in fiscal 2018.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$897.74M | – |
| FY2024 | Dec 31, 2024 | -$557.44M | – |
| FY2023 | Dec 31, 2023 | -$350.57M | – |
| FY2022 | Dec 31, 2022 | -$224.40M | – |
| FY2021 | Dec 31, 2021 | -$147.18M | – |
| FY2020 | Dec 31, 2020 | -$100.06M | – |
| FY2019 | Dec 31, 2019 | -$49.62M | -4190.4% |
| FY2018 | Dec 31, 2018 | $1.21M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$387.32M | – |
| Q1 FY2026 | Mar 31, 2026 | -$354.17M | – |
| Q4 FY2025 | Dec 31, 2025 | -$274.24M | – |
| Q3 FY2025 | Sep 30, 2025 | -$207.31M | – |
| Q2 FY2025 | Jun 30, 2025 | -$221.76M | – |
| Q1 FY2025 | Mar 31, 2025 | -$194.44M | – |
| Q4 FY2024 | Dec 31, 2024 | -$138.29M | – |
| Q3 FY2024 | Sep 30, 2024 | -$130.42M | – |
| Q2 FY2024 | Jun 30, 2024 | -$128.17M | – |
| Q1 FY2024 | Mar 31, 2024 | -$160.56M | – |
| Q4 FY2023 | Dec 31, 2023 | -$120.56M | – |
| Q3 FY2023 | Sep 30, 2023 | -$100.50M | – |
| Q2 FY2023 | Jun 30, 2023 | -$67.12M | – |
| Q1 FY2023 | Mar 31, 2023 | -$62.39M | – |
| Q4 FY2022 | Dec 31, 2022 | -$61.79M | – |
| Q3 FY2022 | Sep 30, 2022 | -$51.74M | – |
| Q2 FY2022 | Jun 30, 2022 | -$55.72M | – |
| Q1 FY2022 | Mar 31, 2022 | -$55.16M | – |
| Q4 FY2021 | Dec 31, 2021 | -$39.27M | – |
| Q3 FY2021 | Sep 30, 2021 | -$36.59M | – |
| Q2 FY2021 | Jun 30, 2021 | -$34.08M | – |
| Q1 FY2021 | Mar 31, 2021 | -$37.25M | – |
| Q4 FY2020 | Dec 31, 2020 | -$25.03M | – |
| Q3 FY2020 | Sep 30, 2020 | -$27.02M | – |
| Q2 FY2020 | Jun 30, 2020 | -$19.99M | – |
| Q1 FY2020 | Mar 31, 2020 | -$28.02M | – |
| Q4 FY2019 | Dec 31, 2019 | -$11.65M | – |
| Q3 FY2019 | Sep 30, 2019 | -$13.86M | – |
| Q2 FY2019 | Jun 30, 2019 | -$11.50M | – |
| Q1 FY2019 | Mar 31, 2019 | -$12.61M | – |